SCHEMBL5974342

SCHEMBL5974342

N[C@H](C=O)Cc1ccc(NC(=O)O)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SLC1A3 P43003 2/20 0.40
SLC1A2 P43004 2/20 0.40
SLC1A1 P43005 2/20 0.40
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
BACE1 P56817 2/20 0.39
SLC7A5 Q01650 2/20 0.39
TAAR1 Q96RJ0 1/20 0.38
LTA4H P09960 1/20 0.38
FOLH1 Q04609 1/20 0.38
ROCK2 O75116 1/20 0.37
ITGB3 P05106 1/20 0.37
ITGAV P06756 1/20 0.37
ITGA2B P08514 1/20 0.37
CRHBP P24387 1/20 0.37
CRHR2 Q13324 1/20 0.37
NPC1 O15118 1/20 0.37
RAB9A P51151 1/20 0.37
ALPI P09923 1/20 0.37
PKM P14618 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2267539 0.85 SMN1; SMN2 (0.52) KMT2AMEN1TAAR1NPC1RAB9A
SCHEMBL27690799 0.85 SMN1; SMN2 (0.52) KMT2AMEN1TAAR1NPC1RAB9A
SCHEMBL2270750 0.85 SMN1; SMN2 (0.52) KMT2AMEN1TAAR1NPC1RAB9A
SCHEMBL28796050 0.83 PTPN1 (0.57) KMT2AMEN1ITGB3ITGAVITGA2B
SCHEMBL14669314 0.83 ROCK2 (0.38) BACE1SLC7A5TAAR1ROCK2CRHBP
SCHEMBL5665191 0.82 PRSS1 (0.35) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL20715008 0.82 PRSS1 (0.35) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL16837053 0.79 ANPEP (0.45) SLC1A3SLC1A2SLC1A1KMT2AMEN1
SCHEMBL14877026 0.78 CA1 (0.38) KMT2AMEN1FOLH1ITGB3ITGAV
SCHEMBL14877027 0.78 CA1 (0.38) KMT2AMEN1FOLH1ITGB3ITGAV

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6753408-B1 DRUGS USED FOR THERAPY ABBVIE INC. 2004-06-22 US claimed
EP-1232183-A2 PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LABORATORIES (US) 2002-08-21 EP claimed
WO-2001038347-A2 PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LABORATORIES (US) 2001-05-31 WO claimed
EP-1232183-B1 PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LAB (US) 2006-01-18 EP disclosed
US-6753408-B1 DRUGS USED FOR THERAPY ABBVIE INC. 2004-06-22 US disclosed
EP-1232183-A2 PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LABORATORIES (US) 2002-08-21 EP disclosed
WO-2001038347-A2 PEPTIDES HAVING ANTIANGIOGENIC ACTIVITY ABBOTT LABORATORIES (US) 2001-05-31 WO disclosed